UMPC
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
French, Esra Karslioglu
NCT04843527: Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes

Active, not recruiting
N/A
350
US
FreeStyle Libre System, FreeStyle Libre System plus food app
Abbott Diabetes Care
Diabetes Mellitus, Type 2
06/25
06/25
Urban, Julie
NCT04056910: Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Completed
2
15
US
ivosidenib and nivolumab
Jason J. Luke, MD, Agios Pharmaceuticals, Inc., Bristol-Myers Squibb
Advanced Solid Tumor, IDH1 Mutation, Glioma
11/23
11/23
KYANITE-1, NCT06228326: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting
1/2
200
US
KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
Krystal Biotech, Inc.
Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
02/28
02/28
STX-001-01, NCT06249048: Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting
1/2
108
US, RoW
STX-001, Keytruda®, Pembrolizumab
Strand Therapeutics Inc.
Advanced Solid Tumor
05/27
11/28
NCT05358379 / 2022-000222-24: A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Recruiting
1/2
330
Europe, US, RoW
CYC140
Cyclacel Pharmaceuticals, Inc., Cyclacel Limited
Solid Tumor, Adult Lymphoma
08/25
11/25
NCT04074967: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Checkmark Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Nov 2022 - Nov 2022: Data in combination with nivolumab in high-risk, PDL1–refractory advanced solid tumors at SITC 2022
Active, not recruiting
1/2
70
US
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Jason J. Luke, MD, Array BioPharma
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
10/24
10/25
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
US
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
07/27
07/27
XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US
XTX301
Xilio Development, Inc.
Advanced Solid Tumor
02/27
02/27
WTX-330x2101, NCT05678998: WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Hourglass Nov 2024 - Nov 2024 : Data from CPI resistant or naive expansion arms for r/r adv tumors
Active, not recruiting
1
75
US
WTX-330
Werewolf Therapeutics, Inc.
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
12/24
02/25
NCT04572451: Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Recruiting
1
50
US
nivolumab, Opdivo®, Anti-PD-1, BMS-986253, Anti-IL-8, Stereotactic Body Radiotherapy (SBRT)
Jason J. Luke, MD, Bristol-Myers Squibb
Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
05/24
05/27
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27

Download Options